Most important is anti-blood-clot medicine Eliquis, which is due to lose patent exclusivity in 2026. Eliquis emerged last year as Pfizer’s top-performing drug, having grown rapidly to bring in $7.4bn ...

Pfizer ( PFE 0.22%) is a case in point, with its forward dividend yield of 7%. Although the stock is a favorite for many income investors, questions about the sustainability of the dividend persist.

Pfizer › Pfizer (NYSE: PFE) has been a terrible investment over the past three years. Revenue and earnings have generally ...

Here is why Pfizer's newfound momentum could set the stock up to soar in 2026. Pfizer's generous dividend has become a big ...